FDA
-
-
-
-
-
-
-
Guerbet: CHMP positive opinion
-
-
-
-
-
-
-
GBT Supports the Sickle Cell Disease Treatment Centers Act of 2022
-
-
-
-
-
-
-
GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 2022
-
-
-
-
-
-
-
GBT Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease
-
-
-
-
-
-
-
The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
-
-
-
-
-
-
-
GBT Announces New Employment Inducement Grants
-
-
-
-
-
-
-
Guerbet: 2021 annual results
-
323,002 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

